Items Tagged ‘refractory’

May 7th, 2015

Adcetris® after Stem Cell Transplant Improves Survival in Hodgkin’s Lymphoma

By

For patients with relapsed or refractory Hodgkin’s lymphoma (HL), treatment with Adcetris® (brentuximab vedotin) after autologous stem cell transplant may improve survival. The Lancet published these findings online. Hodgkin’s lymphoma is a cancer of the lymph system. It typically begins in the lymph nodes in one region of the body and then spreads throughout the […]

View full entry

Tags: adcetris, Autologous Stem Cell Transplant, brentuximab vedotin, HL, Hodgkin's Lymphoma, News, Progressive Relapsed Hodgkin's Lymphoma, refractory, relapsed


February 11th, 2015

NFCR-Support Research Finds New Way to Combat Resistant Lung Cancer

By

A team of researchers at Massachusetts General Hospital has developed a new platform that can rapidly identify effective drug combinations for lung cancer patients whose tumors have stopped responding to targeted therapy. The research, which was supported in part by the National Foundation for Cancer Research (NFCR), is a critical milestone on the road to […]

View full entry

Tags: Extensive Lung Cancer - Small Cell, General Lung Cancer, Lung Cancer, Lung Cancer - Non-Small Cell, Lung Cancer - Small Cell, lung cancer research, News, Recurrent Lung Cancer - Non-Small Cell, refractory, resistant, Stages IIIB-IV Lung Cancer - Non-Small Cell


January 26th, 2015

Further Findings Show Pomalyst plus Low-Dose Dexamethasone Safe and Effective in Relapsed or Refractory Multiple Myeloma

By

For patients with relapsed or refractory multiple myeloma, treatment with Pomalyst® (pomalidomide) plus low-dose dexamethasone appears safe and effective. These findings were presented at the 56th American Hematological Society Annual Meeting and Exposition, December 6–9, 2014, in San Francisco, California.[1] Multiple myeloma is a cancer of plasma cells, which are a special type of white […]

View full entry

Tags: Multiple Myeloma, News, pomalidomide, pomalyst, Recurrent Multiple Myeloma, refractory


November 5th, 2014

Adding Pan-Deacetylase Inhibitor Panobinostat to Velcade and Dexamethasone Improves Progression-Free Survival in Relapsed Myeloma

By

In the phase III PANORAMA1 trial reported in The Lancet Oncology San-Miguel and colleagues found that adding the pan-deacetylase inhibitor panobinostat to Velcade ® (bortezomib) and dexamethasone improved progression-free survival in patients with relapsed or relapsed and refractory multiple myeloma. Multiple myeloma is a cancer of plasma cells, which are a special type of white […]

View full entry

Tags: Multiple Myeloma, News, panobinostat, Recurrent Multiple Myeloma, refractory